BCRX — BioCryst Pharmaceuticals Inc. price, chart and key statistics

Price data

Price

$7.79

YTD price return

-0.13%

YTD total return

-0.13%

Next earnings

Nov 2, 2026

Market cap

2B2016-12 466.9M2026-10 2B+326.1% over the window

Enterprise value

2B

Shares outstanding

255.5M2016-06 73.7M2026-06 255.5M+246.7% over the window

52W low

$6.23

52W high

$11.22

From 52W high

-30.57%

From 52W low

+25.04%

52W range

31%

Volume

Rel volume

0.82×

30D volume

5.4M

30D $ vol

45.3M

Fundamentals

Sales (ttm)

940.6M2016-06 25.2M2026-06 940.6M+3633.2% over the window

Sales/share

$3.682016-06 $0.342026-06 $3.68+976.7% over the window

EPS (ttm)

-$1.632016-06 -$0.982026-06 -$1.63+66.2% over the window

FCF (ttm)

373.4M2016-06 -66.8M2026-06 373.4M-658.9% over the window

FCF/share

$1.462016-06 -$0.912026-06 $1.46-261.2% over the window

Book value/share

-$1.782016-06 $0.182026-06 -$1.78-1078.7% over the window

Net margin

-40.90%2016-06 -285.2%2026-06 -40.9%-85.7% over the window

ROA

-68.96%2016-06 -87.4%2026-06 -69.0%-21.1% over the window

Current ratio

2.322016-06 0.822026-06 2.32+182.8% over the window

Growth (CAGR, ttm) · 10Y

Sales

+68.78%2025-06-30 → 2026-06-30557.5M → 940.6M (+68.7% total)+45.29%2023-06-30 → 2026-06-30306.6M → 940.6M (+206.7% total)+64.07%2021-06-30 → 2026-06-3079.1M → 940.6M (+1088.6% total)+43.62%2016-06-30 → 2026-06-3025.2M → 940.6M (+3633.2% total)

FCF

+2274.13%2025-06-30 → 2026-06-3015.8M → 373.4M (+2269.0% total)n/an/an/a

Shares

+21.75%2025-06-30 → 2026-06-30209.9M → 255.5M (+21.7% total)+10.48%2023-06-30 → 2026-06-30189.5M → 255.5M (+34.9% total)+7.40%2021-06-30 → 2026-06-30178.9M → 255.5M (+42.9% total)+13.24%2016-06-30 → 2026-06-3073.7M → 255.5M (+246.7% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share

+38.63%2025-06-30 → 2026-06-30$2.66 → $3.68 (+38.6% total)+31.51%2023-06-30 → 2026-06-30$1.62 → $3.68 (+127.5% total)+52.77%2021-06-30 → 2026-06-30$0.44 → $3.68 (+732.0% total)+26.83%2016-06-30 → 2026-06-30$0.34 → $3.68 (+976.7% total)

FCF/share

+1850.07%2025-06-30 → 2026-06-30$0.08 → $1.46 (+1846.1% total)n/an/an/a

Price

+15.93%2025-10-16 → 2026-10-16$6.72 → $7.79 (+15.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+9.46%2023-10-16 → 2026-10-16$5.94 → $7.79 (+31.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-12.43%2021-10-15 → 2026-10-16$15.13 → $7.79 (-48.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+6.78%2016-10-14 → 2026-10-16$4.04 → $7.79 (+92.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.

Total return

+15.93%2025-10-16 → 2026-10-16$6.72 → $7.79 (+15.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+9.46%2023-10-16 → 2026-10-16$5.94 → $7.79 (+31.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-12.43%2021-10-15 → 2026-10-16$15.13 → $7.79 (-48.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+6.78%2016-10-14 → 2026-10-16$4.04 → $7.79 (+92.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.

-4.8×2016-12 -6.792026-10 -5.17-23.8% over the window

Fwd P/E

9.0×

P/S (ttm)Market cap ÷ TTM revenue.

2.1×2016-12 21.252026-10 2.11-90.0% over the window

P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.

-4.4×2016-12 116.932026-10 -4.38-103.7% over the window

P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).

5.3×2016-12 -6.512026-10 5.33-181.9% over the window

EV/Sales (ttm)

2.2×

FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.

18.76%2016-09 -15.4%2026-06 14.6%-195.1% over the window

Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 255.5M ÷ 209.9M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.

-21.75%

Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-21.75%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($1.9B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.

-21.75%

Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($2B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.

0.00%2016-09 0.3%2026-06 0.0%-100.0% over the window

Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($2B). Same caveat as the cash buyback yield.

0.00%2016-09 0.3%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/S

1st

P/B

78th